Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Pembrolizumab + Entinostat for Bladder Cancer
Recruiting1 awardPhase 2
Chapel Hill, North Carolina
This trial is testing a new cancer treatment combining immunotherapy with a class I HDAC inhibitor. The goal is to see if the treatment changes immunogenomic markers in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based neoadjuvant chemotherapy.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.